Downregulation of ALDOB is associated with poor prognosis of patients with gastric cancer
Open Access
- 1 October 2016
- journal article
- research article
- Published by Informa UK Limited in OncoTargets and Therapy
- Vol. ume 9, 6099-6109
- https://doi.org/10.2147/ott.s110203
Abstract
Downregulation of ALDOB is associated with poor prognosis of patients with gastric cancer Jun He,1 Yi Jin,1 Yuan Chen,2 Hai-Bo Yao,1 Ying-Jie Xia,3 Ying-Yu Ma,4 Wei Wang,2 Qin-Shu Shao1 1Department of Gastroenterology and Pancreatic Surgery, 2Department of Pathology, 3Key Laboratory of Gastroenterology of Zhejiang Province, 4Clinic Research Institute, Zhejiang Provincial People’s Hospital, Hangzhou, People’s Republic of China Objectives: To examine the expression of ALDOB in gastric cancer (GC) tissue and to reveal its potential clinicopathological and prognostic significance.Materials and methods: We screened for genes that were differentially expressed between GC and nontumor tissues using a microarray, specifically the Affymetrix U133 Plus 2.0 Array platform. We then verified the transcriptional and translational levels of ALDOB by performing quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). In addition, a merged data set based on the Gene Expression Omnibus was generated and a survival analysis performed.Results: The microarray analysis revealed that ALDOB was downregulated (more than sevenfold) in GC compared with nontumor tissue. Both qRT-PCR and IHC validated the decrease of ALDOB in GC tissue. Moreover, we found that the expression of ALDOB was significantly related to tumor-invasion depth, lymph-node metastasis, distant metastasis, and TNM stage. The survival analysis, based on the IHC and merged data set, indicated that the overall survival was better in patients with high ALDOB expression. The Cox regression analysis showed that ALDOB expression was an independent prognostic factor for GC.Conclusion: The expression of ALDOB in GC tissue was significantly related to the clinicopathological features and prognosis of the disease, thus suggesting that ALDOB could act as a novel molecular marker for GC. Keywords: ALDOB, gastric cancer, microarray analysis, molecular markerKeywords
This publication has 34 references indexed in Scilit:
- Assessment of a HER2 scoring system for colorectal cancer: results from a validation studyLaboratory Investigation, 2015
- Genetics and Molecular Pathogenesis of Gastric AdenocarcinomaGastroenterology, 2015
- Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)The Lancet, 2015
- Annual report on status of cancer in China, 20112015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic targetOncology Reports, 2011
- Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative SurgeryWorld Journal of Surgery, 2007
- The structure of human liver fructose-1,6-bisphosphate aldolaseActa Crystallographica Section D-Biological Crystallography, 2001
- The complete amino acid sequence of the human aldolase C isozyme derived from genomic clonesBiochimie, 1987
- Multiple forms of fructose diphosphate aldolase in mammalian tissues.Proceedings of the National Academy of Sciences of the United States of America, 1966